About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

Source: www.news-medical.net Author: staff In a groundbreaking new study, UCLA researchers have for the first time advanced a surgical technique performed with the help of a robot to successfully access a previously-unreachable area of the head and neck. This pioneering method can now be used safely and efficiently in patients to remove tumors that many times were previously thought to be inoperable, or necessitated the use of highly-invasive surgical techniques in combination with chemotherapy or radiation therapy. Developed by Dr. Abie Mendelsohn, UCLA Jonsson Comprehensive Cancer Center member and director of head and neck robotic surgery at UCLA, this new approach provides the surgical community with a leading-edge technology roadmap to treat patients who had little or no hope of living cancer-free lives. "This is a revolutionary new approach that uses highly advanced technology to reach the deepest areas of the head and neck," said Mendelsohn, lead author of the study. "Patients can now be treated in a manner equivalent to that of a straightforward dental procedure and go back to leading normal, healthy lives in a matter of days with few or even no side effects." A New Approach to Saving Lives The parapharyngeal space is pyramid-shaped area that lies near the base of the human skull and connects several deep compartments of the head and neck. It is lined with many large blood vessels, nerves and complex facial muscles, making access to the space via traditional surgical options often impossible or highly invasive. Current surgical techniques can necessitate [...]

2014-12-11T09:25:46-07:00December, 2014|Oral Cancer News|
Read More

Government anti-smoking campaign cost just $480 per quitter, study finds

Source: www.washingtonpost.com Author: Lenny Bernstein At $48 million, the first government mass media campaign to convince cigarette smokers to quit would seem a pricey luxury, especially since that sum purchased just three months of television ads from March through June of 2o12. But a new study of its cost effectiveness, released Wednesday, determined that it cost just $480 for each smoker who quit and $393 per year of life saved. The graphic videos featured pleas from former smokers who had suffered amputated limbs, oral and throat cancer, paralysis, lung damage, strokes, and heart attacks. One of the most haunting showed Terrie Hall, a 52-year-old North Carolina woman whose larynx was removed after she was diagnosed with throat cancer. In the ad, she spoke with the help of an artificial voice box. Hall later died. The campaign and the analysis were both conducted by the Centers for Disease Control and Prevention, but Saul Shiffman, a University of Pittsburgh psychology professor who has spent decades studying smoking habits, said there is no doubt it was a tremendous bargain for the public and, especially, the smokers who quit or added years to their lives. One standard used in studying such interventions considers them cost effective at $50,000 per year of life gained--more than 100 times the cost of the campaigns. Medical interventions, such as heart and lung surgery commonly needed by long-term smokers are much more expensive than that, Shiffman noted. The money spent on the campaign "would pale next to the money [...]

2014-12-11T09:18:54-07:00December, 2014|Oral Cancer News|
Read More

Antacids may improve head and neck cancer survival

Source: www.webmd.com Author: Robert Preidt Using antacids to control acid reflux may improve head and neck cancer patients' chances of survival, a new study suggests. The researchers examined the effects that two types of antacids -- proton pump inhibitors and histamine 2 blockers -- had on head and neck cancer patients. More than two-thirds of the nearly 600 patients in the study took one or both types of the antacids after their cancer diagnosis. Acid reflux -- commonly known as heartburn -- is a common side effect of chemotherapy or radiation treatment, according to the researchers. Proton pump inhibitors include drugs such as Prilosec, Nexium and Prevacid, while histamine 2 blockers include drugs such as Tagamet, Zantac and Pepcid. Compared to patients who didn't take antacids, those who took proton pump inhibitors had a 45 percent lower risk of death, according to the researchers. They also found that those who took histamine 2 blockers had a 33 percent lower risk of death. The study is published in the December issue of the journal Cancer Prevention Research. "We had suspicions that these medications somehow had a favorable impact on patient outcomes. This led us to review our large cohort of patients and screen them for common medications, focusing on antacids. In fact, our study did show that people taking antacids are doing better," study author Dr. Silvana Papagerakis, research assistant professor of otolaryngology--head and neck surgery at the University of Michigan Medical School, said in a university news release. It's not [...]

2014-12-08T13:22:38-07:00December, 2014|Oral Cancer News|
Read More

Red wine: Cancer causing or cancer protective? Researchers say both

Source: Medical News Today Author: David McNamee People who drink red wine have the lowest incidence of cancer caused by alcohol, and researchers think they know why that is. A new study published in the medical journal Advances in Experimental Medicine and Biology explains that while alcohol has cancer causing effects, red wine offers an anti-cancer quality that most other forms of alcohol do not offer. The study was completed by researchers at the University of Colorado Cancer Center. When people first begin to metabolize alcohol, it is converted to acetyl aldehyde, a known carcinogen. “With enough alcohol, the body can get behind and end up with a backlog of acetyl aldehyde,” Dr. Robert Sclafani, the author of the paper, said. As he looked at epidemiological studies of head and neck cancer, he noted that alcohol is a major factor. He explained that when he separated the data into the type of alcohol, it was clear that people who drank red wine seemed to be more protected from cancer. “In red wine, there’s something that’s blocking the cancer-causing effect of alcohol,” Sclafani said. Sclafani believed the resveratrol found in the skin of the grapes used to make red wine removes the most damaged cells from wine drinkers’ bodies. The most heavily damaged cells are also the cells most likely to turn cancerous, according to Medical News Today. “Alcohol bombards your genes,” Sclafani explained. “Your body has ways to repair this damage, but with enough alcohol eventually some damage isn’t fixed. [...]

2019-02-05T12:23:33-07:00December, 2014|Oral Cancer News|
Read More

Hookah smoke increases benzene exposure, risk for leukemia

Source: www.medicalnewstoday.com Author: staff Tobacco use is the leading preventable cause of mortality worldwide and is responsible for the deaths of 6 million people annually. Hookah smoking, a form of tobacco use that employs a partially filled water jar, has come under scrutiny in a new study, which suggests hookah smokers and non-smokers exposed to the smoke have increased uptake of benzene, a substance linked to increased risk of leukemia. Hookah smokers The study is published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. According to the researchers - led by Nada Kassem, associate director at the Center for Behavioral Epidemiology and Community Health at San Diego State University in California - the World Health Organization (WHO) and the US National Toxicology Program have classified benzene as a Group 1 carcinogen. WHO further report that benzene is carcinogenic to humans, recommending that there is no safe level of exposure. Hookah smoke, however, is a source of benzene exposure and is, therefore, a risk factor for leukemia. The most popular kind of hookah tobacco is known as Moassel, which is sweetened and flavored tobacco that contains about 30% tobacco fermented with molasses and fruits mixed with glycerin and chemical flavors. Kassem and her colleagues note that in the US in 2013, it was reported that 26.6% of male and 23.2% of female college students have used hookah at some point in time. Alarmingly, 8.1% of male and 6.6% of female middle and high school [...]

2014-11-25T09:36:27-07:00November, 2014|Oral Cancer News|
Read More

Study: smoking marijuana found non-carcinogenic

Source: americanlivewire.com Author: staff Smoking marijuana does not appear to increase the risk of lung cancer or head-and-neck malignancies, even among heavy users, researchers reported here. “We expected that we would find that a history of heavy marijuana use, more than 500 to 1,000 uses, would increase the risk of cancer from several years to decades after exposure to marijuana, said Donald Tashkin, M.D., of the University of California in Los Angeles. But in fact, they reported at the American Thoracic Society meeting here, marijuana use was associated with cancer risk ratios below 1.0, indicating that a history of pot smoking had no effect on the risk for respiratory cancers. Studies have shown that marijuana contains many compounds that when burned, produce about 50% higher concentrations of some carcinogenic chemicals than tobacco cigarettes. In addition, heavy, habitual marijuana use can produce accelerated malignant change in lung explants, and evidence on bronchial biopsies of pre-malignant histopathologic and molecular changes, Dr. Tashkin said. The investigators had also previously shown that smoking one marijuana cigarette leads to the deposition in the lungs of four times as much tar as smoking a tobacco cigarette containing the same amount of plant material. Marijuana cigarettes are not filtered and are more loosely packed than tobacco, so there’s less filtration of the tar. In addition, pot smokers hold the smoke in their lungs about four times longer than tobacco smokers do, Dr. Tashkin pointed out. For the population-based case-control study, they identified cancer cases among people from [...]

2014-11-25T09:01:35-07:00November, 2014|Oral Cancer News|
Read More

ctDNA ‘Liquid Biopsy’ could revolutionize cancer care

Source: www.medscape.com Author: Janis C. Kelly Bits of tumor cell somatic DNA shed into the circulation or released when cells die can now be detected and counted, thanks to advances in gene sequencing. This circulating tumor DNA (ctDNA) is derived from somatic mutations that occur in the tumor during an individual's life, unlike hereditary mutations that are present in every cell in the body, so ctDNA is a specific cancer biomarker that can be detected, measured, and tracked. Monitoring ctDNA is expected to provide clinicians with faster, cheaper, less invasive ways to assess cancer patients' clinical status and response to therapy. ctDNA assay for multiple genes via next-generation sequencing (NGS) might become a "liquid biopsy" alternative to invasive tissue biopsy, experts told Medscape Medical News. However, they also cautioned that rigorous testing of this concept is needed before the test can be used in practice, saying: "for now, we would counsel clinicians not to jump the gun on this. Faster, Cheaper, More Accurate Tumor Tests Paul B. Chapman, MD, a medical oncologist with the Melanoma and Sarcoma Service at Memorial Sloan Kettering Cancer Center in New York City and Chair of the Medical Advisory Panel at the Melanoma Research Alliance in Washington, DC, said that ctDNA assay is less invasive than biopsy, requires no radiation exposure, is relatively inexpensive, uses fresh DNA not exposed to preservatives, and allows near real-time monitoring of response to treatment. "The beauty of ctDNA monitoring is the speed," Dr Chapman said. "If you are looking [...]

2014-11-19T09:42:11-07:00November, 2014|Oral Cancer News|
Read More

UK researchers improve comfort levels for cancer patients by 3D printing radiotherapy body molds

Source: 3dprint.com Author: Bridget Butler Millsaps Cancer patients undergoing brain or head and neck radiotherapy are required to be immobilized, which is certainly not always popular with those undergoing the procedure, who may already be suffering from anxiety. To make things worse, in order to be immobilized completely during the procedure, it is crucial that they are wearing a fitted mold to prevent motion. Having the mold made is a whole process in itself before the procedure can begin. In a recent study produced by the Journal of Radiotherapy in Practice, over half of the patients describe the process of having a mold made as ‘horrific.’ Many of them also described the process as ‘uncomfortable.’ Topping that off with molded shells that quite often do not fit appropriately, the anxiety levels are heightened for patients — enough so that researchers centered their study around the creation of molded shells through 3D printing that could be created from data conveniently already existing in the form of a CT scan. The process would increase the comfort level for the patient and save a great deal of time in preparing a molding. Radiotherapy is a type of cancer treatment which uses high-energy rays to zap cancer cells. The procedure has to be precisely aimed directly at specific areas to have effect, and it’s not a procedure anyone wants immediately repeated; therefore, It’s important to have the head shell or molding during radiotherapy because the patient must lie still. The mold or shell holds the [...]

2014-11-12T06:54:21-07:00November, 2014|Oral Cancer News|
Read More

Smoking associated with elevated risk of developing a second smoking-related cancer

Source: medicalxpress.com Author: staff Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers. An analysis of five large, prospective cohort studies indicates that lung (stage I), bladder, kidney and head and neck cancer survivors who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to five-fold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked. The association between smoking and developing a second primary smoking-associated cancer was similar to the association between smoking and developing a first primary smoking-associated cancer (patients who smoked more than 20 cigarettes per day had a 5.41-fold higher risk of developing cancer than individuals who have never smoked). Notably, current smoking at any level increased the risk of overall mortality across all cancer disease sites. The study, published on November 10 in the Journal of Clinical Oncology, affirms the 2014 Surgeon General report's conclusion that patients and survivors who smoke are at a higher risk of developing a second cancer. Clinicians term an individual's initial diagnosis a first primary cancer. A second primary cancer is one diagnosed at some point after the first diagnosis. Second primary cancers are not metastases of the first cancer but [...]

2014-11-12T06:41:24-07:00November, 2014|Oral Cancer News|
Read More

Critical Outcome Technologies and MD Anderson Cancer Center to evaluate COTI-2 in treating head and neck cancers

Source: www.marketwatch.com Author: press release Critical Outcome Technologies Inc. ("COTI"), the bioinformatics and accelerated drug discovery company, announced today that it recently executed a material transfer agreement ("MTA") with Dr. Jeffery Myers, MD, PhD, FACS of The University of Texas MD Anderson Cancer Center for the continued evaluation of COTI-2 in the potential treatment of patients with head and neck squamous cell cancer ("HNSCC"). There are approximately 500,000 new cases worldwide of HNSCC a year, making it the sixth leading cancer in terms of new cases. In the United States, HNSCC is considered to be a rare disease and therefore represents a second "Orphan Disease" opportunity for COTI-2. If HNSCC is caught at an early stage, current therapies, which include surgery and radiation followed by chemotherapy, can be effective. Unfortunately, HNSCC tumors with p53 mutations tend to be more difficult to treat with such mutations occurring in 30-70% of HNSCC tumors. These mutations are associated with poorer patient outcomes as traditional chemotherapy, using the current first line chemotherapy, cisplatin, is often ineffective. The overall five-year survival rate of patients with HNSCC is 40-50%. As a small molecule activator of misfolded mutant p53 protein, COTI-2 has demonstrated in preclinical studies its ability to restore p53 function and thus induce cancer cell death for many common p53 mutations. As previously announced, the Company is planning a Phase 1 study in gynecological cancers (ovarian, cervical and endometrial) at MD Anderson with Dr. Gordon Mills and his team and these studies in HNSCC with [...]

2014-10-23T06:30:17-07:00October, 2014|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top